NCT04003636 2026-03-24KEYNOTE-966Merck Sharp & Dohme LLCPhase 3 Completed1,069 enrolled 19 charts 2 FDA
NCT06282575 2026-03-24Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerJazz PharmaceuticalsPhase 3 Recruiting286 enrolled
NCT06109779 2026-03-04Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)AstraZenecaPhase 3 Active not recruiting757 enrolled
NCT03768414 2026-01-12Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract CancersSWOG Cancer Research NetworkPhase 3 Completed452 enrolled 17 charts